share_log

Here's What's Concerning About Kangji Medical Holdings' (HKG:9997) Returns On Capital

Here's What's Concerning About Kangji Medical Holdings' (HKG:9997) Returns On Capital

以下是康基醫療控股(HKG:9997)資本回報率的擔憂
Simply Wall St ·  2022/06/25 20:40

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expanding base of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. Having said that, from a first glance at Kangji Medical Holdings (HKG:9997) we aren't jumping out of our chairs at how returns are trending, but let's have a deeper look.

我們應該尋找什麼樣的趨勢,我們想要找出能夠長期成倍增值的股票?首先,我們希望看到一個經過驗證的退貨關於已使用資本(ROCE)的增長,其次是擴張基地已動用資本的比例。這向我們表明,它是一臺複合機器,能夠不斷地將其收益再投資於企業,併產生更高的回報。話雖如此,從第一眼看康吉醫療控股有限公司(HKG:9997)我們不會因為回報率的趨勢而從椅子上跳起來,但讓我們更深入地看看。

Return On Capital Employed (ROCE): What is it?

資本回報率(ROCE):它是什麼?

Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. To calculate this metric for Kangji Medical Holdings, this is the formula:

如果您不確定,只需澄清一下,ROCE是一種評估公司投資於其業務的資本獲得多少税前收入(按百分比計算)的指標。要計算康基醫療控股的這一指標,公式如下:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

已動用資本回報率=息税前收益(EBIT)?(總資產-流動負債)

0.13 = CN¥418m ÷ (CN¥3.4b - CN¥117m) (Based on the trailing twelve months to December 2021).

0.13=CN元4.18億?(CN元34億-CN元1.17億)(根據截至2021年12月的往績12個月計算).

Therefore, Kangji Medical Holdings has an ROCE of 13%. On its own, that's a standard return, however it's much better than the 10% generated by the Medical Equipment industry.

所以呢,康基醫療控股的淨資產收益率為13%。就其本身而言,這是一個標準的回報,但它比醫療設備行業10%的回報率要好得多。

Check out our latest analysis for Kangji Medical Holdings

查看我們對康吉醫療控股公司的最新分析

SEHK:9997 Return on Capital Employed June 26th 2022
聯交所:9997已動用資本回報率2022年6月26日

Above you can see how the current ROCE for Kangji Medical Holdings compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free report on analyst forecasts for the company.

上面你可以看到康吉醫療控股公司目前的淨資產收益率與之前的資本回報率相比如何,但你只能從過去知道這麼多。如果您感興趣,您可以在我們的免費分析師對該公司的預測報告。

How Are Returns Trending?

回報趨勢如何?

When we looked at the ROCE trend at Kangji Medical Holdings, we didn't gain much confidence. Around four years ago the returns on capital were 59%, but since then they've fallen to 13%. However, given capital employed and revenue have both increased it appears that the business is currently pursuing growth, at the consequence of short term returns. And if the increased capital generates additional returns, the business, and thus shareholders, will benefit in the long run.

當我們觀察康基醫療控股的ROCE走勢時,我們並沒有獲得太多信心。大約四年前,資本回報率為59%,但自那以來已降至13%。然而,鑑於已動用資本和收入都有所增加,該業務目前似乎正在追求增長,這是短期回報的結果。如果增加的資本產生額外的回報,從長遠來看,企業和股東都將受益。

The Key Takeaway

關鍵的外賣

In summary, despite lower returns in the short term, we're encouraged to see that Kangji Medical Holdings is reinvesting for growth and has higher sales as a result. And there could be an opportunity here if other metrics look good too, because the stock has declined 41% in the last year. So we think it'd be worthwhile to look further into this stock given the trends look encouraging.

總而言之,儘管短期內回報較低,但我們感到鼓舞的是,康吉醫療控股正在進行再投資以實現增長,並因此實現了更高的銷售額。如果其他指標也看起來不錯,這可能是一個機會,因為該股在過去一年裏下跌了41%。因此,我們認為,鑑於趨勢看起來令人鼓舞,進一步研究這隻股票是值得的。

One more thing to note, we've identified 1 warning sign with Kangji Medical Holdings and understanding it should be part of your investment process.

還有一件事需要注意,我們已經確定了1個警告標誌與康吉醫療控股公司合作,並理解這應該是您投資過程的一部分。

While Kangji Medical Holdings may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here.

雖然康基醫療控股目前的回報率可能不是最高的,但我們已經編制了一份目前股本回報率超過25%的公司名單。看看這個免費在這裏列出。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論